Lessons learnt inform our approach to new antivascular endothelial growth factor treatments for neovascular age‐related macular degeneration
- 24 October 2013
- journal article
- editorial
- Published by Wiley in Clinical & Experimental Ophthalmology
- Vol. 41 (8), 723-726
- https://doi.org/10.1111/ceo.12212
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular DegenerationOphthalmology, 2012
- Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumabAngiogenesis, 2012
- Delay to Treatment and Visual Outcomes in Patients Treated With Anti-Vascular Endothelial Growth Factor for Age-Related Macular DegenerationAmerican Journal of Ophthalmology, 2012
- Safety and Efficacy of a Flexible Dosing Regimen of Ranibizumab in Neovascular Age-Related Macular Degeneration: The SUSTAIN StudyOphthalmology, 2011
- Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE StudyOphthalmology, 2010
- Predicted biological activity of intravitreal VEGF TrapBritish Journal of Ophthalmology, 2008
- Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1American Journal of Ophthalmology, 2008
- Ranibizumab According to Need: A Treatment for Age-related Macular DegenerationAmerican Journal of Ophthalmology, 2007
- An Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular DegenerationAmerican Journal of Ophthalmology, 2007
- DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATIONRetina, 2006